Successful rechallenge with cetuximab after progression with nivolumab
for recurrent cervical lymph node metastasis from carcinoma of the
tongue
- Yasuyuki Asada
, - Chitoshi Teramura,
- Takuma Wada,
- Yoshisato Machida,
- Shinya Koshinuma,
- Gaku Yamamoto
Abstract
We demonstrate the effectiveness of readministering cetuximab as a
salvage chemotherapeutic agent after nivolumab administration to a
patient with a recurrence of cervical lymph node metastasis after tongue
cancer surgery. We can infer that the immunostimulatory effect of
nivolumab and reactivation of cetuximab enhance the antitumor effect of
the therapy.01 Apr 2021Submitted to Clinical Case Reports 02 Apr 2021Submission Checks Completed
02 Apr 2021Assigned to Editor
02 Apr 2021Reviewer(s) Assigned
06 May 2021Review(s) Completed, Editorial Evaluation Pending
06 May 2021Editorial Decision: Revise Minor
22 May 20211st Revision Received
25 May 2021Submission Checks Completed
25 May 2021Assigned to Editor
25 May 2021Review(s) Completed, Editorial Evaluation Pending
30 May 2021Editorial Decision: Accept
